Nivolumab in metastatic renal cell carcinoma (mRCC) patients: a real world single-center experience

Background: Nivolumab (BMS-936558) is a fully human, IgG4 monoclonal antibody that binds to the PD-1 receptor and by preventing the interaction with its ligands PD-L1 and PD-L2, it disrupts negative signaling and restores T-cell antitumor function. A phase III study (CheckMate 025) has evaluated its efficacy and good safety profile versus everolimus in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with one or two previous...